Evidence map›Paper›PMID 25669755›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2016

Understanding the economic impact of intravascular ultrasound (IVUS).

Alessandro Alberti, Pietro Giudice, Alessandra Gelera, Luca Stefanini, Virginia Priest, Michael Simmonds, Christa Lee, Matthew Wasserman

Abstract read
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Economic Evaluations of Intravascular Imaging Guidance for Percutaneous Coronary Interventions: A Scoping Review.Journal of the Society for Cardiovascular Angiography & Interventions · 2026
    Review
  6. Review
  7. Article
  8. Intravascular Ultrasound Guidance During Peripheral Vascular Interventions: Long-term Clinical Outcomes and Costs From the Japanese Perspective.Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2025
    Observational
  9. CVIT 2025 clinical expert consensus document on intravascular ultrasound.Cardiovascular intervention and therapeutics · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. CVIT 2023 clinical expert consensus document on intravascular ultrasound.Cardiovascular intervention and therapeutics · 2024
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Imaging in Percutaneous Coronary Intervention.Reviews in cardiovascular medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alessandro AlbertiIstituto Clinico Sant'Ambrogio, Milan, Italy.
Pietro GiudiceSan Giovanni Di Dio e Ruggi D'Aragona University Hospital, Salerno, Italy.
Alessandra GeleraBoston Scientific, Milan, Italy.
Luca StefaniniBoston Scientific, Milan, Italy.
Virginia PriestBoston Scientific, Singapore, Singapore.
Michael SimmondsBoston Scientific, Sydney, Australasia.
Christa LeeDouble Helix Consulting, London, UK.
Matthew WassermanDouble Helix Consulting, London, UK. Matthew.wasserman@dhelix.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo examine the cost-effectiveness of intravascular ultrasound (IVUS) use during percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in treating coronary artery disease (CAD). METHODS AND

resultsA Markov model was constructed with a lifetime horizon to compare costs and health outcomes between IVUS-guided PCI and PCI guided solely by angiography from an Italian healthcare payer perspective. The population examined included CAD patients undergoing PCI with DES. From a healthcare payer perspective, the resulting incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year was negative in the base-case scenario (i.e., IVUS benefit assumed to persist beyond the first year). When IVUS benefit was assumed to be limited to the first year, the ICER increased to €9,624. This conclusion remained consistent even when scenarios varied regarding the duration of the device's effect. Furthermore, benefits of using IVUS were greater for patients with acute coronary syndrome, renal insufficiency, and diabetes.

conclusionsUsing IVUS with angiography is a dominant strategy in Italy, and results demonstrate that it is desirable to target those at a greater risk of restenosis (i.e., patients with diabetes, chronic kidney disease, and acute coronary syndrome), who tend to benefit more from accurate stent implantation. Further information is necessary regarding the long-term benefits of IVUS, however sensitivity analysis presented in this research demonstrates a strong argument supporting the cost-effectiveness of IVUS.

Indexed as

Coronary DiseaseCost-Benefit AnalysisDrug-Eluting StentsHealth Care CostsHumansItalyMarkov ChainsMiddle AgedPercutaneous Coronary InterventionQuality-Adjusted Life YearsUltrasonography, InterventionalAngiographyCost-effectiveness analysesDrug-eluting stentEconomic evaluationsIntravascular ultrasoundPercutaneous coronary intervention

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.